Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
Go back to Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 125.31 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.31 | 52 Week High | $118.49 | |||
| Open | $125.31 | 52 Week Low | $55.00 | |||
| Day High | $125.31 | P/E | N/A | |||
| Day Low | $125.31 | EPS | $-0.56 | |||
| Volume | 168 | |||||
